Updated:
Vestal Point Capital
Vestal Point Capital is an investment firm specializing in the life sciences. It manages a diverse portfolio of securities across the biotechnology,...
Overview
Vestal Point Capital is an investment firm specializing in the life sciences. It manages a diverse portfolio of securities across the biotechnology, pharmaceuticals, medical devices, tools, and diagnostics sectors. The firm seeks to capitalize on rapid innovation in healthcare through comprehensive research, industry experience, rigorous risk management and agile execution.
General information
Firm type
Private Equity
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Ryan Wilder
Managing Partner and Chief Investment Officer
Ilko Menkov
Partner, COO and CCO
Charles Adams
Research Analyst
Badre Alkurdy
Research Analyst
Benjamin Carroll
Chief Financial Officer
Tyler DeGeorge
Trading Analyst
Hiro Nagayumi
Research Analyst
Marc Murphy
Head Trader
Rebecca Wheat
Office Manager
Jack Peacock
Research Analyst
Hong Zheng
Research Analyst, Ph.D.
Christian Wilson
Research Analyst
Frequently asked questions
Does Vestal Point participate in fund commitments or only direct deals?
The firm's investment structure — direct equity, fund-of-funds allocations, co-investments, or special-purpose vehicles — is not disclosed. Given the classification as a private equity firm focused on growth, direct or co-investment structures are plausible, but no fund vehicles or LP commitments have been publicly documented.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: